Autolus Therapeutics plc American Depositary Receipt (AUTL)
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?
Autolus Therapeutics PLC Sponsored ADR (AUTL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AUTL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Autolus Therapeutics Q1 Earnings Call Highlights
Autolus Therapeutics NASDAQ: AUTL reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy.
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues and a shift to positive gross margin, with AUTL's cash runway projected into Q4 2027. Key catalysts include pediatric ALL Phase 2 data (2027) and initial MS autoimmune data (late 2026), both with significant upside potential.
Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
New Strong Sell Stocks for January 30th
TSE, PAC and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 30th, 2026.
New Strong Sell Stocks for January 22nd
MHVYF, NFG and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 22, 2026.
Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline
Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline
Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript
Autolus Therapeutics plc ( AUTL ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Amanda Cray Christian Itin - CEO & Director Robert Dolski - Senior VP, CFO & Principal Accounting Officer Conference Call Participants Asthika Goonewardene - Truist Securities, Inc., Research Division Gil Blum - Needham & Company, LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Yuxi Dong - Jefferies LLC, Research Division Madeleine Stone - William Blair & Company L.L.C., Research Division Shyam Kotadia - Goldman Sachs Group, Inc., Research Division Simon Baker - Rothschild & Co Redburn, Research Division Presentation Operator Good day.
Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable
I remain bullish on Autolus Therapeutics as they advance their CAR T-cell therapy, obe-cel, in a competitive leukemia market. Obe-cel shows durable benefits, with 38% of responders at 33 months needing no further therapy, suggesting potential as a definitive treatment. Recent EU approval and expansion into new indications like non-Hodgkin lymphoma and autoimmune diseases strengthen AUTL's market position.
